1010 related articles for article (PubMed ID: 25543402)
21. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
22. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
Rossi ED; Bizzarro T; Martini M; Capodimonti S; Fadda G; Larocca LM; Schmitt F
Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany.
Eszlinger M; Böhme K; Ullmann M; Görke F; Siebolts U; Neumann A; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Ruschenburg I; Paschke R
Thyroid; 2017 Mar; 27(3):402-411. PubMed ID: 28071986
[TBL] [Abstract][Full Text] [Related]
24. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
Pelizzo MR; Boschin IM; Barollo S; Pennelli G; Toniato A; Zambonin L; Vianello F; Piotto A; Ide EC; Pagetta C; Sorgato N; Torresan F; Girelli ME; Nacamulli D; Mantero F; Mian C
Clin Chem Lab Med; 2011 Feb; 49(2):325-9. PubMed ID: 21175381
[TBL] [Abstract][Full Text] [Related]
25. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
26. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
27. Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma.
Lee SH; Jung CK; Bae JS; Jung SL; Choi YJ; Kang CS
Diagn Cytopathol; 2014 Jan; 42(1):11-7. PubMed ID: 23754825
[TBL] [Abstract][Full Text] [Related]
28. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
Meng Z; Lu J; Wu H; Zhao Y; Luo Y; Gao J; Zhu Q; Jiang Y; Li W; Liang Z
Tumour Biol; 2016 Jan; 37(1):611-8. PubMed ID: 26240026
[TBL] [Abstract][Full Text] [Related]
29. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
[TBL] [Abstract][Full Text] [Related]
30. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
Jara SM; Bhatnagar R; Guan H; Gocke CD; Ali SZ; Tufano RP
Head Neck; 2015 Dec; 37(12):1788-93. PubMed ID: 24989827
[TBL] [Abstract][Full Text] [Related]
31. Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.
Pupilli C; Pinzani P; Salvianti F; Fibbi B; Rossi M; Petrone L; Perigli G; De Feo ML; Vezzosi V; Pazzagli M; Orlando C; Forti G
J Clin Endocrinol Metab; 2013 Aug; 98(8):3359-65. PubMed ID: 23788690
[TBL] [Abstract][Full Text] [Related]
32. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
[TBL] [Abstract][Full Text] [Related]
33. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
34. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
Cañadas-Garre M; Becerra-Massare P; López de la Torre-Casares M; Villar-del Moral J; Céspedes-Mas S; Vílchez-Joya R; Muros-de Fuentes T; García-Calvente C; Piédrola-Maroto G; López-Nevot MA; Montes-Ramírez R; Llamas-Elvira JM
Ann Surg; 2012 May; 255(5):986-92. PubMed ID: 22504197
[TBL] [Abstract][Full Text] [Related]
35. Molecular analyses of thyroid tumors for diagnosis of malignancy on fine-needle aspiration biopsies and for prognosis of invasiveness on surgical specimens.
Rousset B; Ziercher L; Borson-Chazot F
Ann Endocrinol (Paris); 2011 Apr; 72(2):125-8. PubMed ID: 21511245
[TBL] [Abstract][Full Text] [Related]
36. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
37. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
38. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
[TBL] [Abstract][Full Text] [Related]
39. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
[TBL] [Abstract][Full Text] [Related]
40. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
